
Partner
One of the world’s largest oncology diagnostics companies. Its biopharma team sells tests to drug developers and runs those partnerships.
Challenge
Its roadmap and sales plan are set well ahead, but each new drug type or late-stage readout changes who needs testing. Market reports were out of date on arrival and never said which sponsors to call.
Approach
In Studio, the team mapped every program and sponsor in four drug types, tied late-stage trials to the patients they’d add, and followed the drugs into autoimmune disease. Monitoring keeps it current.
Outcome
The team decides which tests to build and which sponsors to call from one current view, and reaches each sponsor before it chooses a diagnostic partner.

Each late-stage trial that succeeds changes who gets treated and which diagnostics they need, and most of what’s still open comes after treatment starts. Studio tied every late-stage program in four drug types to the patients that enroll in it, so the team could plan which tests to have ready.

Cell therapies and T-cell engagers are moving into autoimmune disease, so the team can plan tests there early:
Every drug developer picks its partners at set moments, and it usually chooses a diagnostic partner while it designs the pivotal trial. Studio placed every sponsor’s programs on that timeline, so the team can reach them first.


Now the team calls each sponsor before it picks a diagnostic partner, and opens on that sponsor’s own programs.